Table 3.
Demographic characteristics of RA patients observed for 6 months after vaccination.
| RA patients observed for 6 months after vaccination (n=31) | DMARDs added group (n=10) |
no DMARDs added group (n=21) |
p-value | |
|---|---|---|---|---|
| age, years, median (IQR) | 64 (51.5-70) | 58 (51.3-68.8) | 67 (53.0-72.0) | 0.47 |
| female, n (%) | 21 (67.7) | 4 (40.0) | 6 (28.6) | 0.13 |
| duration of RA, year, median (IQR) | 10 (5-16) | 11 (5.8-17.5) | 10 (4-10) | 0.28 |
| RF positivity, n (%) | 25 (80.6) | 8 (80.0) | 17 (81.0) | >0.99 |
| titer, IU/ml, median (IQR) | 63.8 (26.2-126.6) | 51.1 (30.2-123.9) | 68.1 (26.7-117.2) | 0.78 |
| anti-CCP antibody positivity, n (%) | 19 (61.3) | 6 (60.0) | 13 (61.9) | >0.99 |
| titer, U/ml, median (IQR) | 21 (1.2-150) | 76 (1.6-143) | 16.5 (1.08-150.5) | 0.97 |
| fully vaccinated (2 times), n (%) | 31 (100) | 10 (100) | 21 (100) | – |
| systemic inflammation symptoms, n (%) | 11 (29.7) | 3 (30.0) | 8 (38.1) | >0.99 |
| allergy, n (%) | 1 (2.7) | 0 (0) | 1 (4.8) | >0.99 |
| timing of arthralgia after vaccination | ||||
| only after 1st vaccination, n (%) | 2 (6.5) | 0 (0) | 2 (9.5) | >0.99 |
| only after 2nd vaccination, n (%) | 13 (41.9) | 5 (50.0) | 8 (38.1) | 0.70 |
| both after 1st and 2nd time, n (%) | 10 (32.3) | 5 (50.0) | 5 (23.8) | 0.22 |
| unknown, n (%) | 6 (19.4) | 0 (0) | 6 (28.6) | – |
| vaccine type | ||||
| Pfizer-BioTech vaccine, n (%) | 20 (64.5) | 6 (60.0) | 14 (66.7) | >0.99 |
| Moderna vaccine, n (%) | 1 (3.2) | 1 (10.0) | 0 (0) | 0.32 |
| unknown, n (%) | 10 (32.3) | 2 (20.0) | 8 (38.1) | – |
| disease activity score before vaccination | ||||
| DAS28-ESR, median (IQR) | 2.64 (2.3-3.65) | 2.8 (2.22-3.54) | 2.55 (2.37-3.65) | 0.98 |
| CDAI, median (IQR) | 4 (1-9.5) | 3 (1.25-6.725) | 4.5 (1-12) | 0.55 |
| medication before vaccination | ||||
| b/tsDMARDs, n (%) | 8 (25.8) | 0 (0) | 8 (38.1) | 0.03* |
| MTX, n (%) | 21(67.7) | 7 (70.0) | 14 (66.7) | >0.99 |
| other csDMARDs, n (%) | 10 (32.3) | 4 (40.0) | 6 (28.6) | 0.69 |
| PSL combined with DMARDs, n (%) | 7 (22.6) | 5 (50.0) | 2 (9.5) | <0.05 |
IQR, interquartile range; RA, rheumatoid arthritis; RF, rheumatoid factor; DMARDs, disease-modifying antirheumatic drugs; bDMARDs, biologic DMARDs; tsDMARDs, targeted synthetic DMARDs; csDMARDs, conventional synthetic DMARDs; MTX, methotrexate; PSL, prednisolone *P<0.05.